» Articles » PMID: 33488578

CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis

Overview
Journal Front Immunol
Date 2021 Jan 25
PMID 33488578
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

CD80 and CD86 are expressed on antigen presenting cells (APCs) and their role in providing costimulation to T cells is well established. However, it has been shown that these molecules can also be expressed by T cells, but the significance of this observation remains unknown. We have investigated stimuli that control CD80 and CD86 expression on T cells and show that in APC-free conditions around 40% of activated, proliferating CD4 T cells express either CD80, CD86 or both. Expression of CD80 and CD86 was strongly dependent upon provision of CD28 costimulation as ligands were not expressed following TCR stimulation alone. Furthermore, we observed that CD80 T cells possessed the hallmarks of induced regulatory T cells (iTreg), expressing Foxp3 and high levels of CTLA-4 whilst proliferating less extensively. In contrast, CD86 was preferentially expressed on INF-γ producing cells, which proliferated more extensively and had characteristics of effector T cells. Finally, we demonstrated that CD80 expressed on T cells inhibits CTLA-4 function and facilitates the growth of iTreg. Together these data establish endogenous expression of CD80 and CD86 by activated T cells is not due to ligand capture by transendocytosis and highlight clear differences in their expression patterns and associated functions.

Citing Articles

C9orf72 role in myeloid cells: new perspectives in the investigation of the neuro-immune crosstalk in amyotrophic lateral sclerosis and frontotemporal dementia.

Cicardi M, Trotti D Ann Transl Med. 2025; 12(6):120.

PMID: 39817235 PMC: 11729807. DOI: 10.21037/atm-24-86.


New insights into the immunomodulatory potential of sialic acid on monocyte-derived dendritic cells.

Silva Z, Rabaca J, Luz V, Lourenco R, Salio M, Oliveira A Cancer Immunol Immunother. 2024; 74(1):9.

PMID: 39487861 PMC: 11531459. DOI: 10.1007/s00262-024-03863-7.


PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis.

Boumpas A, Papaioannou A, Bousounis P, Grigoriou M, Bergo V, Papafragkos I Front Immunol. 2024; 15:1386838.

PMID: 39464894 PMC: 11502414. DOI: 10.3389/fimmu.2024.1386838.


A Bioinformatics Investigation of Hub Genes Involved in Treg Migration and Its Synergistic Effects, Using Immune Checkpoint Inhibitors for Immunotherapies.

Kim N, Na S, Pyo J, Jang J, Lee S, Kim K Int J Mol Sci. 2024; 25(17).

PMID: 39273290 PMC: 11395080. DOI: 10.3390/ijms25179341.


CD74 supports accumulation and function of regulatory T cells in tumors.

Bonnin E, Rodrigo Riestra M, Marziali F, Mena Osuna R, Denizeau J, Maurin M Nat Commun. 2024; 15(1):3749.

PMID: 38702311 PMC: 11068745. DOI: 10.1038/s41467-024-47981-3.


References
1.
Schmiedel B, Singh D, Madrigal A, Valdovino-Gonzalez A, White B, Zapardiel-Gonzalo J . Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression. Cell. 2018; 175(6):1701-1715.e16. PMC: 6289654. DOI: 10.1016/j.cell.2018.10.022. View

2.
Azuma M, Yssel H, Phillips J, Spits H, Lanier L . Functional expression of B7/BB1 on activated T lymphocytes. J Exp Med. 1993; 177(3):845-50. PMC: 2190946. DOI: 10.1084/jem.177.3.845. View

3.
Hou T, Qureshi O, Wang C, Baker J, Young S, Walker L . A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells. J Immunol. 2015; 194(5):2148-59. PMC: 4522736. DOI: 10.4049/jimmunol.1401876. View

4.
Manzotti C, Liu M, Burke F, Dussably L, Zheng Y, Sansom D . Integration of CD28 and CTLA-4 function results in differential responses of T cells to CD80 and CD86. Eur J Immunol. 2006; 36(6):1413-22. DOI: 10.1002/eji.200535170. View

5.
Lee K, Gudapati P, Dragovic S, Spencer C, Joyce S, Killeen N . Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity. 2010; 32(6):743-53. PMC: 2911434. DOI: 10.1016/j.immuni.2010.06.002. View